PAS
CRDF icon

Point72 Asia (Singapore)’s Cardiff Oncology CRDF Stock Holding History

Point72 Asia (Singapore)’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-49,892
Closed -$266K – 1117
2024
Q1 		$266K Buy
+49,892
New +$133K 0.07% 324

Other funds holding CRDF

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BC
BIT Capital Berlin, Germany $2.07B AUM 157.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Point72 Asia (Singapore)'s CRDF Position: Q2 2024 in Review

Point72 Asia (Singapore) sold out of Cardiff Oncology (CRDF) in Q2 2024, closing a stake of 49,892 shares — an estimated $266K sold.

Point72 Asia (Singapore) first reported a position in CRDF in Q1 2024 and held it in 1 quarter. The position peaked at $266K in Q1 2024. 90 funds tracked by Wall St. Rank hold CRDF as of Q2 2024.

  • Point72 Asia (Singapore) reported no remaining Cardiff Oncology position as of Q2 2024 after selling out during the quarter.
  • Point72 Asia (Singapore) sold 49,892 Cardiff Oncology shares in Q2 2024, an estimated $266K.
  • Point72 Asia (Singapore) first reported a position in Cardiff Oncology in Q1 2024 and held it in 1 quarter.
  • Point72 Asia (Singapore)'s Cardiff Oncology position peaked at $266K in Q1 2024.
  • 90 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2024.

Based on Point72 Asia (Singapore)'s 13F filing for Q2 2024, filed 14 Aug 2024.